Aarti Drugs Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6n00w6o073msixei10f4x5bm.pdf

Key Takeaways


Revenue Walk: What Drove the Quarter

Adhish Patil: "we feel like in the current year, around 10%, we'll try to achieve, though it will be challenging because there has been negative rate variances as far as sales are concerned because as you know, that the input prices have gone down and so are the selling prices."

Margin Mechanics: Inventory Fog and the Recovery Path

Adhish Patil: "Only problem is because all the FIFO techniques, inventory calculation is down FIFO basis, so that is impacting the overall margins of the company when we report it quarter-on-quarter basis. But otherwise, it seems like the margins should be back."

Capex Pipeline: Greenfield Bets and a Delayed Launch

Adhish Patil: "We are confident about the process, what we have developed. We have done piloting also. And as of now, the margin is very high, but then we expect some price cuts from China, some reaction from China."

Segment & Market Dynamics

SegmentTrendCommentary
API (domestic)▲ Strong volume~18% volume growth driven by domestic demand; antibiotics saw heavy buying in Q4 that normalized in Q1.
API (export)▼ ConstrainedUSD shortages in some export geographies slowed growth.
Formulations (export)▲ GrowingStrategic regulatory filings drove a sharp YoY export revenue increase; mix shift from domestic CMO to higher-margin exports underway.
Specialty Chemicals▼ WeakChina dumping at lower prices, campaign-based product absence, and soft demand from LatAm, Europe, and the U.S. Q2 expected slightly better, Q3 better still with an additional product.
Metformin▬ Temporary dipFacility shut for expansion during Q1; volumes expected to grow henceforth after 30% capacity increase to ~1,415 tons/month.
Gliptins▬ Gradual consolidationMarket crowded post-patent; consolidation to 3–4 players expected over 1–3 years, with backward integration helping share gains.

Balance Sheet & Capital Actions


Guidance & Commitments

CommitmentSpecificsTimeline
Quarterly EBITDA exit rateAt least 14.5%–15%Q4 FY24
FY24 revenue growth~10% value growth, assuming current prices, with high-teens volume growthFY24
FY24 capex completionINR250–350 crores, all major projects completed; commercial ops from Q3 FY24FY24
Sequential margin improvementMargins to improve quarter by quarter as high-cost inventory clearsEach quarter through Q4 FY24
Spec chem recoveryQ2 slightly better than Q1; Q3 better still with an additional productQ2 and Q3 FY24
Greenfield utilization (year 1)30%–35% utilization of the two greenfield projectsQ1 FY25
FY25 capexINR100–200 crores including maintenance, if anti-diabetic and side-chain projects startFY25
FY25 EBITDA margin15%–16%, per an analyst’s math that management selected as reasonable; first year of new products limits upsideFY25

Key Metrics

MetricQ1 FY24
Consolidated revenue₹661.7 cr, +6.3% YoY
Standalone revenue₹591.6 cr, +7.3% YoY; 86% of consolidated revenue
EBITDA₹84.7 cr, +26% YoY
EBITDA margin12.8%, improved ~200 bps YoY
PAT₹48 cr, +38% YoY
PAT margin7.3%
Domestic revenue growth (standalone)~13.6% YoY
Export revenue growth (standalone)~-4% YoY
API volume growth~18% YoY, aggregate basis
API price change-8% to -9% YoY, aggregate basis
Formulation segment revenue₹89.9 cr, ~14% of total revenue; 67% from exports
Capex incurred in Q1₹48 cr
Full-year capex guidance₹250 cr to ₹350 cr, inclusive of maintenance capex
Consolidated gross debt₹590 cr
Buyback₹59.85 cr aggregate amount, 6,65,000 shares at ₹900 per share
FY24 revenue growth guidance~10% value growth, assuming current prices and high-teens volume growth
FY24 exit EBITDA margin guidance14% to 15% by Q4 FY24